InvestorsHub Logo
Followers 472
Posts 37018
Boards Moderated 0
Alias Born 01/11/2004

Re: Box Money post# 62675

Sunday, 05/09/2021 2:42:05 PM

Sunday, May 09, 2021 2:42:05 PM

Post# of 118363
David Koos, chairman and chief executive of Regen said: "Because HemaXellerate is a personalized cell therapy product aimed at addressing an unmet medical need, we are in agreement with the FDA in performing the most rigorous safety and efficacy experiments in order to deliver this promising product to patients who at the moment have no other options."

https://www.proactiveinvestors.com/companies/news/119311/regen-biopharma-advances-as-fda-receives-hemaxellerate-data-package-119311.html